CoChat

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Background Minocycline has anti-apoptotic and anti-inflammatory effects in vitro, and extends survival in mouse models of some neurological conditions. Several trials are planned or are in progress to assess whether minocycline slows human neurodegeneration. We aimed to test the efficacy of minocycline as a treatment for amyotrophic lateral sclerosis (ALS).Methods We did a multicentre, randomised placebo-controlled phase III trial. After a 4-month lead-in phase, 412 patients were randomly assigned to receive placebo or minocycline in escalating doses of up to 400 mg/day for 9 months. The primary outcome measure was the difference in rate of change in the revised ALS functional rating scale (ALSFRS-R). Secondary outcome measures were forced vital capacity (FVC), manual muscle testing (MMT), quality of life, survival, and safety. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00047723.Findings ALSFRS-R score deterioration was faster in the minocycline group than in the placebo group (-1.30 vs -1.04 units/month, 95% CI for difference -0.44 to -0.08; p=0.005). Patients on minocycline also had non-significant tendencies towards faster decline in FVC (-3.48 vs -3.01, -1.03 to 0.11; p=0.11) and MMT score (-0.30 vs -0.26, -0.08 to 0.01; p=0.11), and greater mortality during the 9-month treatment phase (hazard ratio=1.32, 95% CI 0.83 to 2.10; p=0.23) than did patients on placebo. Quality-of-life scores did not differ between the treatment groups. Non-serious gastrointestinal and neurological adverse events were more common in the minocycline group than in the placebo group, but these events were not significantly related to the decline in ALSFRS-R score.Interpretation Our finding that minocycline has a harmful effect on patients with ALS has implications for trials of minocycline in patients with other neurological disorders, and for how potential neuroprotective agents are screened for use in patients with ALS.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(07)70270-3

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Research works printed but not linked: 4

  1. Almer, 2001, Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis, Ann Neurol, 49, 176, 10.1002/1531-8249(20010201)49:2<176::aid-ana37>3.0.co;2-x · doi:10.1002/1531-8249(20010201)49:2<176::aid-ana37>3.0.co;2-x
  2. Florence, 2004, Validation of telephonic administration of the ALSFRS-R, Neurology, 62, A134
  3. Stambler, 1998, Prognostic indicators of survival in ALS, Neurology, 50, 66, 10.1212/wnl.50.1.66 · DOI · Paper page
  4. 1999, A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III), Neurology, 52, 1427, 10.1212/wnl.52.7.1427 · DOI · Paper page

Cited by

See all 715

Metadata

Authors
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., Neville, H. E., Boylan, K., Mozaffar, T., Belsh, J. M., Ravits, J., Bedlack, R. S., Graves, M. C., McCluskey, L. F., Barohn, R. J., & Tandan, R.
Affiliations
  • Columbia University Irving Medical Center (US)
  • California Pacific Medical Center (US)
  • Washington University in St. Louis (US)
  • Mayo Clinic in Arizona (US)
  • Columbia University (US)
  • University of California, San Francisco (US)
  • University of Colorado Health (US)
  • University of California, Irvine (US)
  • University of Medicine and Dentistry of New Jersey (US)
  • Virginia Mason Medical Center (US)
  • Duke University (US)
  • University of California, Los Angeles (US)
  • University of Pennsylvania (US)
  • University of Kansas (US)
  • University of Vermont (US)
Corresponding author
Gordon, Paul H
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2007-12
Volume
6
Issue
12
Pages
1045-1053
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2144536780
Cited by
649
References
47
Citations by year
2026: 8 · 2025: 15 · 2024: 15 · 2023: 19 · 2022: 26 · 2021: 21 · 2020: 30 · 2019: 19 · 2018: 26 · 2017: 37 · 2016: 32 · 2015: 44 · 2014: 39 · 2013: 57 · 2012: 57
FWCI
34.77
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Rutgers University Community Repository (Rutgers University) (submittedVersion)
Funders
  • Muscular Dystrophy Association
  • National Institute of Neurological Disorders and Stroke (R01 NS45294)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
minocycline, amyotrophic lateral sclerosis, neuroprotection, neurodegeneration, anti-inflammatory activity, anti-apoptotic effects, forced vital capacity, mortality, adverse events
MeSH terms
Aged, Amyotrophic Lateral Sclerosis, Anti-Bacterial Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Minocycline, Psychomotor Performance, Quality of Life, Vital Capacity, Confidence Intervals, Survival Analysis, Outcome Assessment, Health Care, Muscle, Skeletal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. https://app.cochat.ai/papers/10.1016/s1474-4422(07)70270-3
The paper
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., Neville, H. E., Boylan, K., Mozaffar, T., Belsh, J. M., Ravits, J., Bedlack, R. S., Graves, M. C., McCluskey, L. F., Barohn, R. J., & Tandan, R. (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(07)70270-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.